Baltimore, MD – University of Maryland Biotechnology Institute’s (UMBI) President Dr. Jennie Hunter-Cevera announced that Stephen J. Trevisan, founder, President and CEO of Accelovance, is joining the UMBI Board of Visitors. UMBI is Maryland’s premier biotechnology research institute.
Mr. Trevisan is an entrepreneur who has founded four companies since 1987 and has considerable experience in the management of service providers in the biotechnology and pharmaceutical industries. He co-founded his first company, National Clinical Research Centers (NCRC) in 1987. NCRC was a clinical Contract Research Organization (CRO) specializing in phase II-IV clinical studies. The company deployed a unique method for conducting clinical trials using company owned facilities and mass media advertising for patient recruitment. NCRC grew from 2 employees in 1987 to 250 in 1992. It became highly successful and was sold in 1992. In 1994, Mr. Trevisan founded CommSys Corporation a provider of outsourced billing services to the telecommunications industry. After two years of exceptional growth and profitability, the company was sold to Perot Systems in 1996. Mr. Trevisan remained with Perot in a leadership role in their Communication and Media practice until December of 1998 when he founded TherImmune Research Corporation (TRC). TherImmune was a CRO specializing in pre-clinical and early stage clinical drug development services for the pharmaceutical, biotech and government markets. In four years, the company grew sales to $27.5 million with 250 employees. The company was sold in April 2003 to Gene Logic Inc. at a significant profit. In June 2004, Mr. Trevisan founded Accelovance where he is currently president and CEO. Accelovance provides CRO services to the biopharmaceutical industry with operations in the United States and Peoples Republic of China.